Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug-delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its...
WINT - nov 26 : Wind-tree Is Studying Istaroxime in Early Cardiogenic Shock Patients WARRINGTON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the results of U.S. hospital claims...
Watch for a break of 2.42. Stop signal 1.92, First target 3.32, 2nd target momentum.
Proof is in the number. Get the app its worth it.
-Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 32% at $2.63 in Friday's premarket session after Oppenheimer initiated coverage on the stock with an Outperform rating and an $8 price target. -Windtree Therapeutics is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. The...
Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes a synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactant without invasive procedures. Its development program utilizing its...
Fallen Angel with Recent Insider Buying. Stop signal 1.96. Target 1 @ 2.87, Target 2 @ 3.93. Target 3@ 6.93.
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases.
call it as pre fifth wave. one more downtrend before correcting higher imo. best, matt